- Home
- TSI vs LFCR Comparison
TSI vs LFCR Comparison
Compare TSI & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSI | LFCR |
|---|---|---|
| Founded | 1987 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 190.9M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TSI | LFCR |
|---|---|---|
| Price | $4.46 | $4.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 115.6K | ★ 223.0K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $4.43 | $3.63 |
| 52 Week High | $5.06 | $8.98 |
Technical Indicators
Market Signals| Indicator | TSI | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 38.45 |
| Support Level | $4.43 | $4.22 |
| Resistance Level | $4.58 | $5.35 |
| Average True Range (ATR) | 0.03 | 0.33 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 14.29 | 13.19 |
Price Performance
Historical ComparisonAbout TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a diversified closed-end management investment company. The investment objective of the company is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as banks, beverages, biotechnology, chemicals, commercial services, and others.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.